Market Overview

Emblem launches Atmosphere, its first oral dose-metered spray

Share:

TORONTO, Sept. 13, 2018 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV:EMC, OTCQX:EMMBF) ("Emblem" or the "Company"), through its wholly-owned subsidiary Emblem Cannabis Corporation, a licensed producer of medical cannabis under the Access to Cannabis for Medical Purposes Regulations ("ACMPR"), today announced the launch of its first oral dose-metered spray, Emblem Atmosphere. Designed with patients' needs in mind, Atmosphere ensures a precise dose with each spray and a convenient medication delivery system. Atmosphere is available in four different formulations, offering patients and healthcare professionals choice to meet a variety of health goals.

"The launch of Atmosphere is further reinforcement of Emblem's core focus on creating new, innovative and unique products that help patients – Emblem's first and foremost priority. Atmosphere oral sprays were developed to help patients better manage their symptoms through precise dosing of their cannabis medication," said Nick Dean, CEO, Emblem Corp. "This latest product launch is a testament to the incredible work being done by Emblem's medical division. Precise dosing in each oral spray allows patients to easily track medication use and adjust use as needed. Atmosphere sprays also provide patients with a cleaner and more discreet experience."

Atmosphere oral dose-metered sprays use the same formulations as Emblem's line of cannabis oils including 0:20 CBD Oil, 12:20 Balanced CBD Oil, 20:0 Indica Dominant Oil and 20:0 Sativa Dominant Oil. Each formulation is chemovar-specific to ensure product consistency. Atmosphere sprays are developed using MCT oil, a pharmaceutical-grade carrier oil that is flavour-neutral, odourless and shelf-stable.

The oral sprays are intended to be administered sublingually, with each spray delivering 0.1 ml of oil, or roughly 2 mg of active ingredients. Atmosphere comes in a 15 ml cannister, with 150 sprays per bottle. 

For more information visit https://emblemcannabis.com/collection/extracts/.

About Emblem
Emblem, through its wholly-owned subsidiary Emblem Cannabis Corporation, is a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada under the ACMPR. Emblem's state-of-the-art indoor cannabis cultivation facility and research and development laboratory is located in Paris, Ontario. Led by an experienced management team of healthcare executives, accomplished marketing professionals, and cannabis experts, Emblem is focused on driving shareholder value through product innovation, brand relevance, and access to patient and consumer channels. Emblem is also the parent company of GrowWise Health Limited, one of Canada's leading cannabis education services. Emblem trades under the ticker symbol EMC on the TSX Venture Exchange.

For media inquiries, please contact:

Morgan Cates
H+K Strategies
416-413-4649
Morgan.cates@hkstrategies.ca

For other inquiries, please contact:

Ethan Karayannopoulos
Investor Relations 
Emblem Corp. 
647.748.9696 
ethank@emblemcorp.com

Alex Stojanovic
Chief Financial Officer
Emblem Corp. 
416.923.1331
alexs@emblemcorp.com    

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward-looking statements") within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "may", "will", "project", "should" or similar words, including negatives thereof, suggesting future outcomes. Management of the Company believes the expectations reflected in such forward-looking statements are reasonable as of the date hereof but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. Various material factors and assumptions are typically applied in drawing conclusions or making the forecasts or projections set out in forward-looking statements. Those material factors and assumptions are based on information currently available to the Company, including data from publicly available governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which Emblem believes to be reasonable. However, although generally indicative of relative market positions, market shares and performance characteristics, such data is inherently imprecise. While Emblem is not aware of any misstatement regarding any industry or government data presented herein, the medical marijuana industry involves risks and uncertainties and is subject to change based on various factors.

Forward-looking statements are not a guarantee of future performance and are subject to and involve a number of known and unknown risks and uncertainties, many of which are beyond the control of the Company, which may cause the Company's actual performance and results to differ materially from any projections of future performance or results expressed or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, the risks identified in the Company's December 31, 2017 Management's Discussion and Analysis, which has been filed with the Canadian Securities Administrators and available on www.sedar.com. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.

EM-Logo-4c_300.png

View Comments and Join the Discussion!